OXCARBAZEPINE
Clinical safety rating: caution
Animal studies have proved adverse effects but may be safe for humans
Stabilization of neuronal membranes by blockade of voltage-sensitive sodium channels, leading to inhibition of repetitive firing and reduction of neurotransmitter release.
| Metabolism | Primarily hepatic via cytosolic enzymes (not CYP450) to active metabolite 10,11-dihydro-10-hydroxy-carbazepine (MHD); minor CYP3A4 involvement. |
| Excretion | Renal: 70% (mainly as glucuronide metabolites, unchanged drug <1%). Fecal: negligible. |
| Half-life | Oxcarbazepine: 2 hours (parent drug); MHD (active metabolite): 9 hours. Steady-state achieved in 2-3 days. Context: shorter t1/2 than carbamazepine; MHD t1/2 extended in renal impairment (up to 19 hours). |
| Protein binding | Parent drug: 60% (albumin). MHD: 40% (albumin). Binding is concentration-independent and does not significantly displace other drugs. |
| Volume of Distribution | Parent drug: 0.5 L/kg; MHD: 0.75 L/kg. Vd indicates moderate tissue distribution and crosses the blood-brain barrier. |
| Bioavailability | Oral: >95% (parent drug extensively metabolized to MHD; bioequivalent to suspension and tablets). IV: not available. |
| Onset of Action | Oral: 1-3 hours (peak MHD concentration). Clinical effect may be seen within 1 week but full effect may require 2-4 weeks. |
| Duration of Action | Oral: approximately 12 hours (consistent with twice-daily dosing). Duration correlates with MHD half-life; requires regular dosing to maintain therapeutic levels. |
Initial 300 mg orally twice daily; increase by 300 mg/day every third day to target dose of 600-1200 mg/day in two divided doses. Maximum 2400 mg/day.
| Dosage form | TABLET |
| Renal impairment | CrCl <30 mL/min: initiate at 150 mg twice daily and titrate slowly. Hemodialysis: administer a supplemental dose of 150 mg after dialysis. |
| Liver impairment | Mild to moderate hepatic impairment (Child-Pugh A or B): no dose adjustment required. Severe hepatic impairment: use with caution; no specific dose guidelines. |
| Pediatric use | 2-16 years: initiate at 8-10 mg/kg/day (max 600 mg/day) in two divided doses. Increase by 5 mg/kg/day every third day to target 20-30 mg/kg/day (max 900 mg/day for 2-4 years, 1200 mg/day for 4-12 years, 1800 mg/day for 12-16 years). |
| Geriatric use | Initiate at lower dose (150 mg twice daily) and titrate slowly due to age-related decrease in creatinine clearance and higher risk of hyponatremia. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Strong CYP3A4 inducers may decrease levels of active metabolite Can cause hyponatremia and cross-hypersensitivity with carbamazepine.
| Breastfeeding | Oxcarbazepine and its active metabolite MHD are excreted into breast milk. The M/P ratio for MHD is approximately 0.5. Relative infant dose estimated at 2-4% of maternal weight-adjusted dose. Concentrations in milk vary with maternal dose and timing. Although generally considered compatible with breastfeeding, monitor infant for drowsiness, poor feeding, and adequate weight gain. Benefits of breastfeeding likely outweigh minimal risk of adverse effects. |
| Teratogenic Risk | Pregnancy Category D. First trimester exposure increases risk of major congenital malformations, particularly neural tube defects, orofacial clefts, and cardiac anomalies. Mechanism involves active metabolite MHD inhibition of voltage-gated sodium channels critical for early embryogenesis. Risk of neural tube defects is approximately 0.5-1% (vs. 0.1% baseline). Later trimester exposure may cause neonatal hemorrhage due to vitamin K deficiency and neonatal withdrawal syndrome characterized by jitteriness, feeding difficulties, and respiratory distress. Risks persist throughout pregnancy, with potential cognitive and behavioral effects in offspring. |
■ FDA Black Box Warning
None.
| Common Effects | Headache Nausea Vomiting Fatigue Dizziness Nystagmus involuntary eye movement Tremors Vertigo Drowsiness Abnormality of voluntary movements Abnormal gait Visual disturbance Increased sodium level in blood |
| Serious Effects |
["Hypersensitivity to oxcarbazepine or eslicarbazepine","History of angioedema with previous treatment"]
| Precautions | ["Risk of hyponatremia (monitor sodium levels)","Hypersensitivity reactions including Stevens-Johnson syndrome (especially in HLA-B*1502 positive patients)","Suicidal ideation risk","Withdrawal seizures if abruptly discontinued","Dizziness, somnolence, and coordination abnormalities","Teratogenicity (Pregnancy Category D)"] |
Loading safety data…
| Fetal Monitoring | Pre-pregnancy: Assess folate status and supplement with 4-5 mg/day folic acid due to increased risk of neural tube defects. First trimester: Targeted ultrasound and optional amniocentesis for neural tube defects. Second trimester: Detailed fetal anomaly scan at 18-22 weeks. Throughout pregnancy: Monitor maternal serum drug concentration (total and free MHD) every trimester if clinically indicated; goal therapeutic concentration (usually 10-35 mcg/mL for MHD). Assess for signs of toxicity (dizziness, ataxia, diplopia) and efficacy (seizure control). Assess for vitamin K deficiency after 36 weeks; administer oral vitamin K 10 mg/day to mother from 36 weeks to delivery. Postpartum: Check infant for withdrawal symptoms and coagulopathy. |
| Fertility Effects | May cause reversible decreases in sperm count and motility in males due to endocrine effects, including increased sex-hormone binding globulin and reduced free testosterone. In females, may cause menstrual irregularities, anovulatory cycles, and reduced fertility due to hormonal imbalance. Polycystic ovary syndrome has been associated with oxcarbazepine use. Discontinuation may improve fertility parameters. |